Over 10 years we help companies reach their financial and branding goals. Maxbizz is a values-driven consulting agency dedicated.




411 University St, Seattle


JFL Life Sciences Limited SME IPO – NSE Emerge opens on 25th August 2022; Intends to raise Rs 1,816.58 Lakhs through 29,78,000 equity shares – Business Standard

Sponsored Content is a “Paid For” Press Release distribution arrangement. Purely a Commercial Arrangement, brands and advertisers pay to be featured and to get this content published.
The Editorial/Content team at Business Standard has not contributed to writing/editing this article.
To get your brand featured in this Section write to assist@bsmail.in

New Delhi [India], August 25 (ANI/PNN): JFL Life Sciences Limited, engaged in the business of manufacturing pharmaceutical products having experience of more than a decade, is all set to raise Rs 1,816.58 Lakhs through an initial public offering (IPO). The issue opens on the 25th of August and will be listed on NSE Emerge.
The public issue of JFL Life Sciences Limited is of 29,78,000 equity shares of Face Value Rs 10 each (“EQUITY SHARES”) for cash at a price of Rs 61/- per equity share (including a securities premium of Rs 51/- per equity share) (the issue price) aggregating Rs 1,816.58 LACS of the issue. 1,50,000 equity shares aggregating to Rs 91.50 Lakhs will be reserved for market maker (“Market Maker Reservation Portion”). The issue, less the Market Maker Reservation Portion, i.e., issue of 28,28,000 equity shares of Face Value of Rs 10/- EACH at an issue price of Rs 61/- per equity share, aggregating to Rs 1,725.08 Lakhs, which is hereinafter referred to as “The Net Issue”. The issue and the Net Issue will constitute 27.08 per cent and 25.71 per cent, respectively of the post issue paid up equity share capital of the company. The company will list at NSE Emerge. The Lead manager of the issue is GYR Capital Advisors Pvt Ltd and the Registrar to the issue is KFin Technologies Ltd. The issue opens on August 25 and will close on August 30, 2022 and will subsequently be listed on NSE Emerge.
The company intends to utilize the proceeds of the Issue to meet the following objectives:
1. Repayment of secured and unsecured loans
2. Funding the working capital requirements of the company
3. General Corporate Purposes

JFL Life Sciences Limited is engaged in the business of manufacturing pharmaceutical products. Their product portfolio consists of Dry powder injections (B-Lactam), Tablets and Capsules (B-Lactam) solid oral dosage form and Tablet and capsules (general) Solid Oral Dosage Form and Oral rehydration solutions (ORS). With market presence in pan India, products of JFL supplies to 10 developed and developing countries throughout the World. To maintain its competitiveness and to further the cause of health care JFL has laid a strong R & D foundation and an FDA approved state of the art manufacturing facility near Ahmedabad.
The Company has registered their products to manufacture in various countries like sovereign of Kenya, Nigeria, Yemen and Myanmar. Few of their products are also registered with Ukraine, Uzbekistan, and Kazakhstan as well. This also makes them a ‘one-stop-shop’ service provider for catering to all of the customer’s needs domestically as well as internationally.
The promoters, Smiral Ashwinbhai Patel and Tejal Smiralbhai Patel are actively involved in the day-to-day business of the company and are the guiding force behind the strategic decisions for the Company. Their management team and other key management personnel are well qualified and have extensive industry expertise, and have been responsible for the operational growth.
This Story has been provided by PNN. ANI will not be responsible in any way for the content in this article. (ANI/PNN)

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor
Copyrights © 2022 Business Standard
Pvt Ltd. All rights reserved.



Joseph Muongi

Financial.co.ke was founded by Mr. Joseph Muongi Kamau. He holds a Master of Science in Finance, Bachelors of Science in Actuarial Science and a Certificate of proficiencty in insurance. He's also the lead financial consultant.